posted under $80k revenue in 4C quarterly. sold off on this expectation and sold off even more after.The story is same, blue sky product, but little in the way of actual sales. forget about earnings.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%